Inhibition the MAP3K20-mediated ribotoxic stress response pathway downregulates M1 macrophage polarization in

Wan-Yu Xia1, Xin-Yuan Ma2, Zi-Meng Zhu1

  • 1Acupuncture and Moxibustion School, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.

PubMed

Insights

This study reveals how ribotoxic stress response (RSR) drives M1 macrophage polarization in ulcerative colitis (UC). Targeting MAP3K20 kinase with Vemurafenib shows promise for treating UC by reducing inflammation.

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Ulcerative colitis (UC) involves complex immune dysregulation.
  • M1 macrophage polarization contributes to UC pathogenesis.
  • Ribotoxic stress response (RSR) role in UC is not fully understood.

Purpose of the Study:

  • Investigate RSR activation of M1 macrophage polarization in UC.
  • Identify key genes and pathways involved in RSR-mediated M1 polarization in UC.
  • Evaluate MAP3K20 as a therapeutic target for UC.

Main Methods:

  • Gene Set Variation Analysis (GSVA) of intestinal tissues.
  • Weighted gene co-expression network analysis (WGCNA) for RSR hub genes.
  • Single-cell RNA sequencing.
  • Dextran Sodium Sulfate (DSS)-induced UC models.

Main Results:

  • Identified six core RSR hub genes (SNAL1, MDM2, MAPK11, MAP3K20, E2F1, BMP6).
  • Established MAP3K20 as the pivotal kinase in RSR-mediated M1 macrophage polarization in UC.
  • MAP3K20 regulates JNK/p38 signaling, driving M1 polarization and UC inflammation.
  • Vemurafenib (MAP3K20 inhibitor) attenuated inflammation and pathological damage in UC models.

Conclusions:

  • MAP3K20 is a key mediator of RSR-driven M1 macrophage polarization in UC.
  • Targeting MAP3K20 offers a potential therapeutic strategy for ulcerative colitis.
  • This research provides novel insights into UC pathogenesis and treatment.